Stephen Ellis

A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma

P. Szlosarek, J. Bomalaski, M. Sheaff, 2022, Pigment cell & melanoma research.

Role of 3'-Deoxy-3'-[18F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase

V. Goh, P. Szlosarek, L. Pike, 2022, JTO clinical and research reports.

A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma

T. Crook, P. Szlosarek, R. Jena, 2019, Clinical Cancer Research.

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial

S. Beck, J. Shamash, L. Butcher, 2017, JAMA oncology.

Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer

P. Szlosarek, J. Bomalaski, M. Sheaff, 2021, Cancer medicine.

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

J. Shamash, P. Szlosarek, J. Spicer, 2020, JTO clinical and research reports.

Phase 1 study of pegargiminase combined with cisplatin and pemetrexed in patients with ASS1-deficient uveal melanoma.

P. Szlosarek, J. Bomalaski, M. Sheaff, 2018 .

Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer

M. Ychou, E. Assenat, D. Botsen, 2021, JAMA network open.